Welcome to Novo Nordisk in the United States

print email
Latest News
Jun 23, 2018

Findings from CONFIRM – a large, retrospective real-world evidence (RWE) study comparing the effectiveness of Tresiba® (insulin degludec injection) 100 U/mL, 200 U/mL versus insulin glargine...

Jun 23, 2018

Ozempic® (semaglutide) injection 0.5 mg or 1 mg provided greater weight reductions vs dulaglutide 0.75 mg or 1.5 mg, respectively, in adults with type 2 diabetes, regardless of baseline body mass...

Jun 23, 2018

Oral semaglutide, an investigational GLP-1 receptor agonist taken as a once-daily tablet, achieved significant reductions in blood sugar versus placebo in adults with type 2 diabetes, according to...

Jun 23, 2018

Xultophy® 100/3.6 (insulin degludec and liraglutide injection) 100 units/mL and 3.6 mg/mL provided superior A1C reduction compared to insulin glargine U-100 (1.94% vs 1.68% respectively;...

Download Center

Visit the download center to download Novo Nordisk video and more

Stay Connected

Sign up to receive our new alerts
via e-mail